Related Experiment Video
Updated: Mar 2, 2026
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
Obinutuzumab is Effective in Chronic Lymphocytic Leukemia and Rheumatoid Arthritis After Rituximab Failure: A Case
Curtis Lachowiez1, Atul Deodhar2, Eliana Kozin3
1Department of Medicine, Oregon Health and Science University, Portland, OR, USA.
Insights
Obinutuzumab, an anti-CD20 antibody, achieved sustained remission in a patient with both chronic lymphocytic leukemia (CLL) and rheumatoid arthritis (RA). This highlights the potential of targeted therapy for managing multiple co-existing conditions.
Area of Science:
- Hematology
- Immunology
- Rheumatology
Background:
- Chronic lymphocytic leukemia (CLL) is a prevalent leukemia in older adults, often presenting with comorbidities.
- Management of CLL requires consideration of co-existing conditions like rheumatoid arthritis (RA).
- Monoclonal antibodies (mAbs) have transformed treatment paradigms across various diseases, including hematologic malignancies and autoimmune disorders.
Observation:
- A patient with progressive CLL and rheumatoid symptoms experienced treatment failure with rituximab.
- The patient was subsequently treated with obinutuzumab, a second-generation anti-CD20 antibody.
Findings:
- Obinutuzumab therapy resulted in simultaneous, sustained remission of both CLL and rheumatoid arthritis.
- This led to the discontinuation of all other disease-modifying anti-rheumatic drugs (DMARDs).
- Prolonged remission of CLL was observed during obinutuzumab treatment.
Implications:
- Anti-CD20 antibodies demonstrate efficacy in both hematologic malignancies and inflammatory conditions.
- Obinutuzumab shows promise for managing simultaneous, distinct disease states by targeting shared pathways.
- Further evaluation of obinutuzumab's role in rheumatoid arthritis is warranted.
Abstract:
BACKGROUND Chronic lymphocytic leukemia (CLL) is the most common leukemia affecting older adults. As such, many of these patients suffer from co-existing disease states, and the provider must take these comorbidities into account when determining a treatment regimen. The widespread use of monoclonal antibodies (mAbs) has drastically changed the treatment landscape of multiple diseases, ranging from leukemia to autoimmune conditions such as rheumatoid arthritis. CASE REPORT We present the case of a patient who had progression of his CLL and rheumatoid symptoms on rituximab therapy, and was subsequently treated with the second-generation anti-CD20 antibody obinutuzumab. Obinutuzumab therapy was associated with simultaneous sustained remission of both disease states, allowing for discontinuation of all other disease-modifying anti-rheumatic drugs (DMARDs), and prolonged remission of his CLL. CONCLUSIONS While anti-CD20 antibodies have a clear role in the treatment of leukemia and inflammatory conditions, the success of obinutuzumab in RA has not been fully evaluated. We present this case as further evidence of the strong role of anti-CD 20 therapy in multiple conditions, and the unique opportunity for control of simultaneous disease states through targeted inhibition of shared common pathways.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
02:56Treatment Resistant Cancers
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents